News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
JeeSuk Chang: The 2nd analysis of SABR-5
JeeSuk Chang/X
Feb 24, 2025, 14:08

JeeSuk Chang: The 2nd analysis of SABR-5

JeeSuk Chang, Radiation Oncologist at Yonsei Cancer Center, shared an article by Sarah Baker, et al. on X:

“Check out the 2nd analysis of SABR-5!

Honored to be part of this team.

Ultracentral tumors = distant/widespread mets PFS/OS (despite similar LC).

Re-emphasizing the importance of risk-adapted dosing and strict OAR constraints.”

The Impact of Ultracentral Tumor Location on Outcomes in Patients with Pulmonary Oligometastases: A Secondary Analysis of the Single-Arm Phase 2 SABR-5 Trial.

Authors: Sarah Baker, et al.

JeeSuk Chang: The 2nd analysis of SABR-5

cancer fight against cancer Global fight against cancer JeeSuk Chang OncoDaily Oncology pulmonary oligometastases RadOnc SABR-5 Sarah Baker Ultracentral Tumor Yonsei Cancer Center
Special Coverage
Oncolibrary
Apr 25, 2025, 02:46
FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma
Career
Apr 24, 2025, 21:39
Triparna Sen: I am thrilled and humbled to be nominated as a candidate for the IASLC Board of Directors
Blog
Apr 24, 2025, 21:05
Liz O’Riordan: 25 things I wish I had known before I got breast cancer
Blog
Apr 24, 2025, 20:53
Signing Ceremony of MoU Between Doha University for Science and Technology and Qatar Cancer Society
Blog
Apr 24, 2025, 20:40
Yan Leyfman: How AI is transforming cancer care - from improving diagnosis to reducing disparities
Insight
Apr 24, 2025, 20:28
Fernando Campos: We revealed a harsh Brazilian reality in Sarcoma Study
Insight
Apr 24, 2025, 19:38
George Vlachogiannis: Black patients were less likely to receive nephrectomy compared to non-Hispanic White patients
Blog
Apr 24, 2025, 18:30
Paolo Tarantino: Recent ADCs took a median time of 7 years from clinical introduction to approval
Blog
Apr 24, 2025, 17:56
Milestones from Philippine Cervical Cancer Elimination Operational Plan Workshop - APAC Women's Cancer Coalition
Blog
Apr 24, 2025, 17:55
Julie S. Torode: Attending my first ever AACR conference this week - long over due
Blog
Apr 24, 2025, 17:41
The Ohio State’s James Cancer Hospital and Solove Research Institute Welcomes Dr. Kimryn Rathmell as New CEO
Blog
Apr 24, 2025, 17:36
Bishal Gyawali: WHO EML working group discussion on checkpoint inhibitors for solid cancers